C. Ola Landgren, MD, PhD, discusses what is next for chimeric antigen receptor T-cell therapy in the multiple myeloma landscape.
C. Ola Landgren, MD, PhD, chief of Myeloma Service and hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses what is next for chimeric antigen receptor (CAR) T-cell therapy in the multiple myeloma landscape.
Landgren thinks the field is about to reach its potential since there are several CAR T cells that are autologous; these are going after the same target, so remaining questions now include which agent be the winner or will there be room for multiple CAR T therapies? The upcoming data will show what is best for patients with multiple myeloma. It may depend on which therapy is easier to give, which could be given in the outpatient setting, and which is safer. He says if there is a difference in efficacy, that would also generate an answer as to which agent is best, but right now it is uncertain.
There are also specific antibodies in development at the same time as these CAR T-cell therapies are being researched. For patients with multiple myeloma, there are many bi-specific antibodies being investigated. There are 5 to 10 of them right now that go after BCMA and CD3, and there are also tri-specific antibodies in development that have co-stimulatory domains, according to Landgren. CAR T cells and the bi-specific therapies are both quickly moving forward, as well as possible tri-specifics. He says the winner will be a combination, but the future will tell.
<< View more resources and information regarding CAR T-cell therapy
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More